Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Bacterial Meningitis
Interventions
BIOLOGICAL

Meningococcal ACWY conjugate vaccine

All subjects received a single dose of Meningococcal ACWY conjugate vaccine

Trial Locations (4)

400012

Seth GS Medical College and KEM Hospital, Mumbai

411018

Padmasree Dr. D.Y Patil medical College, Pune

411043

Bharati Vidyapeeth University Institutional Ethics Commitee, Katraj

500004

Osmania Medical College Ethics Commitee, Niloufer Hospital, Hyderabad

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY

NCT01547715 - Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India | Biotech Hunter | Biotech Hunter